China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

Alteogen公司近日宣布，其已与第一三共（Daiichi Sankyo）达成独家许可协议。第一三共将获得在全球范围内使用ALT-B4 ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

今日，美国盖伦基金会（TheGalien Foundation）公布了素有“医药界的诺贝尔奖”之称的盖伦奖（PrixGalien USA Awards）得奖名单。该奖项表彰为改善人类健康做出的杰出科学创新，被认为是医药和生物医疗行业的最高荣誉之一。

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

Breast cancer drug blocked for NHS use as price talks break down for third time - Nice said it was ‘extremely disappointed’ ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...